It looks like HRV level of accuracy is nearly commercially possible for optical wearables with an announcement from Valencell, below.
It has been demonstrated before at several shows but I would assume that association with medical-grade usage, even if only implied by the joint FDA/CTA axhibition, is a good thing.
Jabra, who also embed Valencell technology, have been talking about HRV for a couple of years using ear-based optical HRM. The ear seems to be one of the most accurate locations for a good reading.
ESSENTIAL READING: Jabra Sport Pulse Review
Why do I mention this? Other than an unhealthy interest in HRV I probably should also bring to your attention that Suunto’s 3rd release for 2016 will be an optical HR version of the SPARTAN SPORT. And, you’ve guessed it, it will use Valencell technology for that 🙂 – Presumably their PERFORMTEK technology.
Draw your own conclusions…
———-Press Release below, in full —————
Valencell Showcases Innovations in Biometric Health Wearables at Digital Health Technology Expo sponsored by the Consumer Technology Association and U.S. Food and Drug Administration
Raleigh, N.C. and WASHINGTON, D.C. – Sept. 26, 2016 – Valencell, the leading innovator in performance biometric data sensor technology, announced today that it is among a select group of technology and consumer electronics companies invited to exhibit at the Digital Health Technology Expo, sponsored by the U.S. Food and Drug Administration (FDA) and the Consumer Technology Association (CTA) on Monday, September 26, 2016 at the FDA’s headquarters in Silver Spring, Maryland. Other companies exhibiting include Philips, Qualcomm, Sony, Samsung, Fossil/Misfit, and Validic, among others.
Valencell will be demonstrating its groundbreaking biometric sensor technology and its ability to accurately measure RR-interval in wearable devices worn in numerous form-factors. Accurate RR-interval data is critical to the wearable health monitoring marketplace because this data is required for assessments of heart rate variability (HRV), atrial fibrillation, arrhythmia, stress analysis, and various cardiovascular conditions.
The Expo will feature presentations from the CTA, FDA, the U.S. Department of Health and Human Services, as well as additional government, academic and industry market leaders on consumer technology’s critical role in advancing healthcare. Sessions will discuss innovations in biometric wearables for healthcare data delivery; ways in which innovators and regulators can work collaboratively to drive innovation in healthcare technology; and how patient generated data can create positive change in healthcare delivery through empowering patients and caregivers to drive positive behavior change and reduce health risks, leading to better treatment and outcomes.
“We are honored to be invited by the CTA and FDA to participate in this event, and to have the opportunity to showcase some of our latest innovations in biometric data sensor technology for health applications, including accurate continuous RR-interval monitoring technology that can ultimately be used for important health screening applications and fitness assessments,” said Dr. Steven LeBoeuf, president and co-founder of Valencell. “The goal of Valencell’s innovation in wearable technology is to make biometric monitoring easy, affordable, and seamless with everyday living, so that more accurate data can be taken frequently enough to drive personalized health insights and guidance. We look forward to working with government and industry groups, and our partners, to help drive continued growth in this market.”
Valencell PerformTek® sensor systems are the most accurate, robust and flexible technology available today, powering more biometric hearables and wearables on the market than any other company. The technology gives hearable devices the ability to continuously and accurately measure blood flow signals even during extreme physical activity or when the optical signals are weak. These signals can be translated into accurate, motion-tolerant biometric data, including continuous heart rate, VO2 and VO2 max, resting heart rate, heart rate response, heart rate recovery, continuous energy expenditure (calorie burn), cardiac efficiency and heart rate variability (HRV) assessments.
Valencell licenses its biometric sensor technology through product licensing and patent licensing, to enable customers to create custom-designed biometric hearable and wearable devices. Valencell also introduced Benchmark™, a turnkey biometric sensor system with the complete PerformTek technology package ready for immediate integration into wearable and hearable devices.
Valencell has the most cited patent portfolio in wearable PPG in the industry, which includes 37 patents granted and more than 70 additional patents pending.
The accuracy of Valencell’s PerformTek technology has been independently validated by numerous research institutions, including Duke University, NC State University, and the American College of Sports Medicine.
Valencell’s PerformTek technology is the choice of popular consumer electronics brands, including Samsung, Sony, LG, Intel, Jabra, Scosche, Atlas Wearables, Caeden, Kuaiwear, Bioconnected, and iRiver among numerous others. To learn more about licensing PerformTek, visit valencell.com/access.
About Valencell
Valencell develops performance biometric sensor technology and licenses this patent-protected technology to consumer electronics manufacturers, mobile device and accessory makers, sports and fitness brands and gaming companies for integration into their products. Valencell’s PerformTek® biometric sensor technology employs biophysical signal characterization to actively characterize biophysical signals for removing physical noise and extracting highly accurate biometric information. Valencell’s PerformTek-powered sensors are the most accurate wearable biometric sensors that continuously measure heart rate and activity. Valencell has invested years into the research and development of its PerformTek sensor technology, protected by dozens of granted patents and independently validated by the Duke Center for Living, North Carolina State University, the Human Performance Laboratory and a fellow of the American College of Sports Medicine.